Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis
Top Cited Papers
- 1 April 2021
- journal article
- review article
- Published by Elsevier BV in European Journal of Pharmacology
- Vol. 897, 173926
- https://doi.org/10.1016/j.ejphar.2021.173926
Abstract
No abstract availableKeywords
Funding Information
- U.S. Food and Drug Administration (2020a)
- U.S. Food and Drug Administration (2020a)
- National Institute of Allergy and Infectious Diseases (2020a)
This publication has 37 references indexed in Scilit:
- RoB 2: a revised tool for assessing risk of bias in randomised trialsBMJ, 2019
- One‐sample aggregate data meta‐analysis of mediansStatistics in Medicine, 2018
- Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading ExoribonucleasemBio, 2018
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronavirusesScience Translational Medicine, 2017
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventionsBMJ, 2016
- Publication Bias: The Elephant in the ReviewAnesthesia & Analgesia, 2016
- Convincing Evidence from Controlled and Uncontrolled Studies on the Lipid-Lowering Effect of a StatinPublished by Wiley ,2012
- Cognitive-behavioural interventions for children who have been sexually abusedEmergencias, 2012
- Virus-encoded proteinases and proteolytic processing in the NidoviralesJournal of General Virology, 2000
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996